Accelerated Medicines Partnership
AMP Update September 2014
NIH announces network to accelerate medicines for rheumatoid arthritis and lupus
"The Arthritis Foundation is proud to be a part of this groundbreaking partnership," said Amanda Niskar, DrPH, MPH, BSN, national scientific director, Arthritis Foundation, "For people with arthritis, these awards offer a tangible hope for not only a better understanding of these diseases, but also for the development of greater diagnostic and treatment options."
The National Institutes of Health has awarded grants to 11 research groups across the United States to establish the Accelerating Medicines Partnership in Rheumatoid Arthritis and Lupus (AMP RA/Lupus) Network. Launched in February of this year, the NIH AMP Program is a public-private partnership developed to transform the current model for identifying and validating the most promising biological targets for the development of new drugs and diagnostics. Through a competitive process, the AMP RA/Lupus Network Leadership Center and Research Sites were selected, and $6 million of first-year funding was awarded on Sept. 24, 2014. The network will implement the goals of the broader AMP RA/Lupus Program. Learn more.
The Arthritis Foundation is part of an exciting new initiative, the Accelerating Medicines Partnership (AMP). AMP is a new venture that brings together the Foundation for the National Institutes of Health (FNIH), the National Institute of Health (NIH), 10 bio pharmaceutical companies and several non-profit organizations to work toward a common goal of earlier drug discovery and development for diseases, including rheumatoid arthritis and lupus.
As part of this cross-sector partnership, we will be able to share expertise and resources in a way that enables the best informed contributions to science. One critical component of this partnership is that industry partners will make the data and analysis resulting from AMP available to the broader bio-medical community.
The first pilot projects will begin in three disease areas:
- Alzheimer’s Disease
- type 2 diabetes
- autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus)
The pilot projects will be three to five years in length and aimed at characterizing effective molecular indicators of disease called biomarkers and distinguishing biological targets most likely to respond to new therapies. For more information about AMP, click here.